An interventional study of Listening to Women & Pregnant and Postpartum People in Mental Health Issue, Substance Use Disorders and Postpartum Depression, sponsored by Medical University of South Carolina. Active, not recruiting at 1 site in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Medical University of South Carolina · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies in Substance-Related Disorders by Medical University of South Carolina — 6 open to participants now, 9 under way, none of them phase 3. Substance-Related Disorders · Medical University of South Carolina.
Among the 48 studies in Substance-Related Disorders by Medical University of South Carolina, this one has the largest enrollment of the 47 interventional ones that give a count, is one of 2 that started in 2023, is one of 24 with no phase, and was the 39th registered.
2,242 studies on the registry are indexed under Substance-Related Disorders; 408 are open to participants now.
Browse Substance-Related Disorders studies →6 of the 48 studies in Substance-Related Disorders by Medical University of South Carolina are open now, in 1 country. Recruiting first, the newest first:
Medical University of South Carolina · Sites in United States
Ages 21–45
Medical University of South Carolina · Sites in United States
Ages 18–45 · Women only
Medical University of South Carolina · Sites in United States
Ages 21+ · Healthy volunteers
Medical University of South Carolina · Sites in United States
Ages 18–70
Medical University of South Carolina · Sites in United States
Ages 21–65
By country, each count listing its studies:
Of the 266 Substance-Related Disorders studies recruiting now, 130 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 90 take healthy volunteers.
This study: 18 Years to 45 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 18 · Phase 4 2
First in 1992; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10,469 is above the median of 108 across 1,844 interventional studies indexed under Substance-Related Disorders.
Median enrollment 81 across the 47 interventional studies, 24 across the 1 observational. Of the 38 that completed or were terminated, 18 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
Medical University of South Carolina is the lead sponsor of 875 studies on the registry; 165 are open to participants now.
Of its 132 completed or terminated interventional studies of FDA-regulated products, 104 (79%) have results posted.
4 of the studies in Substance-Related Disorders by Medical University of South Carolina that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04998916Medical University of South CarolinaMPFC Theta Burst Stimulation as a Treatment Tool for Alcohol Use Disorder: Effects on Drinking and Incentive Salience | 2026-12-31 |
| NCT05384223Medical University of South CarolinaEvaluation of RRFT for Co-occurring SUD and PTSD Among Teens | 2027-02-28 |
| NCT05764213Medical University of South CarolinaImproving Maternal Mental Health & SUD Screening and Treatment | 2027-07-31 |
| NCT06641115Medical University of South CarolinaIntegrated Treatment for Opioid Use Disorder and PTSD | 2027-08 |
Add all 4 to your calendar (.ics) → With an account.
Among the 48 studies in Substance-Related Disorders by Medical University of South Carolina, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to compare a text message-based mental health and substance use screening and referral to a treatment program, called Listening to Women and Pregnant and Postpartum People (LTWP), to standard of care in-person mental health and substance use screening to look at rates of treatment attendance and retention in treatment. Participation would involve completing online questionnaires. You may be eligible to participate if you are age 18-45 years, are pregnant and entering prenatal care in one of MUSC's OB clinics, and attended a prenatal appointment at an MUSC clinic.
Aim 1: To determine differences in rates of treatment attendance and retention for Perinatal Mood and Anxiety Disorders (PMADs) and Perinatal Substance Use Disorders (PSUDs) between participants assigned to LTWP, compared to SBIRT.
Aim 2: To determine differences in Patient-Reported Outcomes (PROs) including depressive symptoms, quality of life, substance use, and maternal functioning and well-being measured at baseline and 2, 5, 8, and 11 months postpartum.
Aim 1:
This study is a cluster RCT step wedge design so we are randomizing on the clinic level, not the individual level. The clinics are made up of 4 "wedges" (3 clinics/wedge). Pregnant women receiving prenatal care in these clinics will receive SBIRT as part of usual care. Clusters of clinics will be randomized to an LTWP start date where they will transition from SBIRT to LTWP for the purposes of screening and referral to treatment.
EHR Data Collection (PPP):
Inclusion:
Exclusion:
a.) primary language is not English or Spanish
Aim 2:
Study Assessments at baseline and 2, 5, 8, and 11 months postpartum (PPP):
Inclusion:
Exclusion:
This group will receive in-person screening and referral to treatment assessment.
This group will receive text-message-based SBIRT with phone-based assessment and referral to treatment. The SBIRT is a survey with 9 questions related to depression, anxiety, substance abuse (alcohol, cigarettes, and other drugs including prescription medication), and domestic violence.
Behavioral: Listening to Women & Pregnant and Postpartum People
Participants are enrolled in text message-based screenings with immediate automated feedback, paired with remote care coordination and, if appropriate, home-based telemedicine mental health and substance use disorder treatment services.
Change in Treatment Attendance
Treatment attendance is defined as attending at least 1 or more visits with a mental health or substance use disorder treatment provider.
Time frame: Through participants baseline prenatal care appointment and pregnancy and the postpartum year for participants, approximately 21 months
Change in Retention in Treatment
Retention in treatment for PMADs: defined as 6 or more psychotherapy visits and/or 4 or more medication management visits; and PSUDs: are defined as continuous pharmacological and/or behavioral treatment \> 2 months.
Time frame: Through participants baseline prenatal care appointment and pregnancy and the postpartum year for participants, approximately 21 months
Change in depressive symptoms
We will compare the mean change in the Edinburgh Postnatal Depression Scale (EPDS) among those assigned to LTWP compared to SBIRT. A score of 10 or more on the EPDS suggests clinically elevated depressive symptoms requiring further evaluation. A higher score on the EPDS is a worse outcome.
Time frame: Change from baseline depression screening symptoms to follow-up depression screening symptoms during the postpartum year, approximately over 21 months.
Change in Substance Use
We will compare the change in substance use frequency and amount as measured by the ASSIST among those assigned to LTWP compared to SBIRT. A score of 0-3 (0-4 for cannabis) has an indicated response for brief education, a score of 4-26 (5-26 for cannabis) has an indicated response for brief intervention, a score of 27+ has an indicated response for brief intervention (offer options that include treatment).
Time frame: Change from baseline substance use to follow-up substance use during the postpartum year, approximately over 21 months.
Change in Maternal Functioning and Wellbeing
We will compare the change in maternal functioning measured by the Barkin Index of Maternal Functioning among those assigned to LTWP compared to SBIRT. Each item is rated on a 7-point likert scale ranging from 0 = "strongly disagree" to 6 = "strongly agree". The total score ranges from 0 to 120. Higher levels of functioning are associated with higher total scores with 120 representing optimal functioning. Lower levels of functioning are associated with lower scores.
Time frame: Change from baseline maternal functioning to follow-up maternal functioning during the postpartum year, approximately over 21 months.
Started Apr 2023 (actual). Primary completion is estimated for Jul 2027, 51 months after the start.
Of 819 non-industry interventional studies with no phase under Substance-Related Disorders, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 53. This study's planned 51 months is above that.
Counting every sponsor, half of 859 studies reached it within 34 months; a quarter within 17 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of South Carolina →